Actinium Pharmaceuticals announces significant findings from ASH 2026, revealing Iomab-ACT's promise in CAR T-cell therapy and sickle cell disease treatment.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Tuesday, May 6 - 8:47am EDT (TheFly subscription required to read more.)

Actinium Pharmaceuticals has received significant patent allowances for its Actimab-A and Iomab-ACT initiatives, strengthening its patent protection in key global markets.

Actinium Pharmaceuticals has commenced its innovative CAR-T trial at the University of Texas. Initial clinical data is anticipated by late 2025.

Actinium Pharmaceuticals presents significant advancements in its treatments for myeloid malignancies during an update event at Mar-a-Lago.

Actinium Pharmaceuticals (NYSE American: ATNM) received two Canadian patent allowances covering its Actimab-A and Iomab-ACT programs. These patents extend protection for Actimab-A plus CLAG-M in AML and CD45-targeted conditioning for gene-edited cell therapies, reinforcing a global estate of about 250 patents and applications, with Canadian terms into 2038 and 2039.

Actinium Pharmaceuticals (NYSE: ATNM) has enrolled its first patient in a groundbreaking trial of Iomab-ACT, a targeted radiotherapy conditioning agent, with commercial CAR-T therapy at the University of Texas Southwestern Medical Center. Initial clinical data is expected in H2 2025. The trial aims to replace traditional chemotherapy conditioning agents with Iomab-ACT to reduce serious CAR-T related toxicities. The technology targets CD45, a cell surface marker on immune cells, and has shown promising results in previous trials with zero cases of ICANS and minimal CRS. This development could significantly impact the CAR-T therapy market, which generated $4 billion in sales in 2024 and is projected to reach $12 billion by 2030. The addressable market includes approximately 150,000 patients annually across approved CAR-T therapy indications.

Actinium Pharmaceuticals holds investor event at Trump's Mar-a-Lago resort, discussing Actimab-A and Iomab-ACT programs. CEO Sandesh Seth announces

Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or...

- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of...

- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical...

- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Clinical proof of concept data expected in 2H:2025 from Actimab-A…

Actinium Pharmaceuticals holds investor event at Trump's Mar-a-Lago resort, discussing Actimab-A and Iomab-ACT programs. CEO Sandesh Seth announces